In 2018, the global HIV diagnostics market was worth US$ 3,050.8 million, and it is predicted to grow at a 9.2% CAGR over the forecast period (2019-2027)

In HIV prevention, treatment, care, and other support services, HIV tests play a critical role. HIV testing options in health-care facilities, as well as a variety of community-based initiatives including HIV self-testing, are all available for HIV diagnosis.

The HIV diagnostics industry is predicted to rise as a result of increased government activities.

Because of increased government initiatives to combat HIV infection, the HIV Diagnostics Market is likely to rise significantly. For example, the Ministry of Health and Family Welfare of the Government of India released the 'Test and Treat Policy for HIV' policy in April 2017, which is projected to increase the longevity and quality of life of HIV-positive people. In addition, Sri Lanka's Ministry of Health launched the National HIV/STI Strategic Plan (NSP) Sri Lanka 2018-2022 in 2017. This strategic plan outlines five goals that will help NSP achieve its goal of eliminating new HIV infections, discrimination, and AIDS-related fatalities in the country.

As the need for HIV Diagnostics Market at home grows, prominent manufacturers are focusing their efforts on producing portable, easy-to-use, and quick-to-diagnose tests. As a result, market growth is likely to accelerate. For example, the Therapeutic Goods Administration approved Atomo Diagnostics' Atomo HIV Self-Test for sale in Australia in November 2018. (TGA). It is Australia's first and only HIV diagnostic self-test to be approved by the national regulator.

Because HIV Diagnostics Market competitors are increasingly adopting agreement and partnership methods, the HIV diagnostics market is predicted to grow significantly. For example, Mylan N.V. and Atomo Diagnostics formed a cooperation in September 2019. Mylan received commercialization rights for Atomo's HIV fast diagnostic throughout Africa, Asia, the Middle East, and the Commonwealth of Independent States as part of the cooperation.

The rising number of HIV Diagnostics Market cases that go undetected or are diagnosed late is fueling demand for HIV diagnostics, which is likely to boost market growth over the forecast period. For example, according to the European Centre for Disease Prevention and Control (ECDC) study from 2017, over 51% of all HIV cases in Europe were detected late in 2015, and around 28% had advanced HIV infection. Furthermore, in nine European nations, including Austria, Estonia, Greece, Italy, Latvia, Lithuania, Romania, Slovenia, and Sweden, the rate of late diagnoses was greater than 50%.

Players to Watch

Abbott Laboratories, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol-Myres Squibb, Janssen Therapeutics, QIAGEN N.V., and ViiV